Stock listing

KRX:006280 GC Biopharma Corp. (녹십자) 주가

Follow GC Biopharma Corp. into a list and get an email when it puts out news.

Share price · KRX:006280

₩130,200 KRW -1,800 (-1.4%)

Close on Oct 30, 2026

Past year +0.9% · daily closes, Oct 30, 2025 – Oct 30, 2026, adjusted for splits
Day range
₩128,100 – ₩133,400 KRWOct 30, 2026
Volume
25,903 sharesOct 30, 2026
Market cap
₩1.49T KRWAt the close on Oct 30, 2026 · price × 11.41M shares outstanding
52-week range
₩105,900 – ₩183,800 KRWLowest and highest trades, Oct 31, 2025 – Oct 30, 2026
Traded on an average day
₩3.18B KRWMedian day 19,256 shares · last 3 months, Jul 30, 2026 – Oct 30, 2026
GC Biopharma Corp. logo

Daily closes

Last 3 months, Jul 30, 2026 – Oct 30, 2026 · KRX:006280 · KRW, adjusted for splits

DayCloseChange%OpenHighLowVolume
₩130,200-1,800-1.4%₩133,100₩133,400₩128,10025,903
₩132,000+1,500+1.1%₩130,100₩132,000₩129,60014,411
₩130,500+1,400+1.1%₩129,100₩132,700₩129,00012,863
₩129,100-500-0.4%₩129,700₩131,300₩128,40016,808
₩129,600-2,600-2.0%₩130,700₩132,900₩128,60014,259
₩132,200+1,200+0.9%₩130,900₩133,500₩129,10028,926
₩131,000-400-0.3%₩130,200₩133,000₩128,80020,320
₩131,400-1,300-1.0%₩133,300₩137,500₩130,70028,919
₩132,700+2,000+1.5%₩129,300₩134,400₩128,60029,031
₩130,700+3,100+2.4%₩127,500₩130,900₩126,60018,750
₩127,600+2,600+2.1%₩126,500₩130,600₩125,50020,186
₩125,000-2,400-1.9%₩127,900₩130,800₩123,10015,487
₩127,40000.0%₩126,800₩130,300₩125,80015,944
₩127,400-700-0.5%₩127,200₩127,500₩123,20018,861
₩128,100-1,300-1.0%₩129,200₩130,700₩127,00015,883
₩129,400-1,100-0.8%₩130,500₩130,500₩127,90030,053
₩130,500+3,000+2.4%₩129,200₩131,000₩127,70026,923
₩127,500+1,700+1.4%₩126,500₩130,500₩126,40022,805
₩125,800-3,500-2.7%₩129,100₩129,800₩124,30014,875
₩129,300+6,300+5.1%₩124,400₩129,600₩123,40033,177
₩123,000-200-0.2%₩123,800₩124,700₩121,30021,185
₩123,20000.0%₩124,300₩124,600₩121,40012,951
₩123,200-100-0.1%₩123,400₩124,800₩122,60012,578
₩123,30000.0%₩123,800₩125,400₩123,10014,262
₩123,300-2,400-1.9%₩125,700₩126,300₩123,10018,851
₩125,700+3,300+2.7%₩122,000₩126,500₩121,90018,164
₩122,400-300-0.2%₩124,200₩124,200₩120,700117,126
₩122,700+300+0.2%₩123,600₩124,200₩122,00012,744
₩122,400-2,500-2.0%₩126,000₩126,300₩121,60017,432
₩124,900-1,700-1.3%₩126,300₩127,400₩124,80015,789
₩126,600-1,700-1.3%₩127,100₩128,000₩124,80015,217
₩128,300-1,800-1.4%₩128,300₩131,100₩127,20020,355
₩130,100+2,700+2.1%₩126,100₩130,100₩125,40026,875
₩127,400+400+0.3%₩127,000₩127,700₩126,10015,358
₩127,000-300-0.2%₩128,400₩128,500₩126,10017,150
₩127,300-300-0.2%₩128,800₩128,800₩125,70013,558
₩127,600+600+0.5%₩128,200₩128,800₩125,5009,199
₩127,00000.0%₩127,900₩131,300₩125,70017,766
₩127,000-1,100-0.9%₩127,800₩131,900₩126,70019,181
₩128,100-1,000-0.8%₩127,900₩129,300₩127,20013,517
₩129,100-1,400-1.1%₩128,900₩129,300₩125,70017,348
₩130,500+3,400+2.7%₩126,300₩130,600₩125,50018,676
₩127,100-3,400-2.6%₩130,600₩130,900₩126,20015,160
₩130,500+4,200+3.3%₩129,100₩131,000₩127,10019,330
₩126,300-4,000-3.1%₩127,600₩129,500₩124,00021,796
₩130,300+8,200+6.7%₩124,900₩131,100₩124,20041,331
₩122,100-3,300-2.6%₩122,800₩123,700₩120,00029,371
₩125,400+4,400+3.6%₩133,500₩133,800₩123,70065,683
₩121,000-800-0.7%₩119,500₩121,800₩119,20013,205
₩121,800-7,400-5.7%₩128,000₩128,600₩120,30036,434
₩129,200-300-0.2%₩129,100₩130,300₩127,60015,571
₩129,50000.0%₩129,400₩131,500₩128,30033,035
₩129,500-3,200-2.4%₩131,500₩133,500₩129,20029,911
₩132,700-400-0.3%₩132,700₩136,000₩131,40029,828
₩133,100+3,200+2.5%₩128,900₩133,200₩128,30023,205
₩129,900+3,400+2.7%₩124,400₩129,900₩124,40028,612
₩126,500+4,200+3.4%₩121,000₩127,000₩121,00034,608
₩122,300+2,300+1.9%₩118,800₩125,300₩118,80041,286
₩120,000+6,700+5.9%₩112,300₩120,200₩112,20051,245
₩113,300-2,600-2.2%₩114,000₩114,500₩105,90057,670
₩115,900+1,700+1.5%₩113,400₩116,500₩112,50030,013
₩114,200+1,000+0.9%₩108,600₩118,700₩108,10059,451
Ticker
KRX:006280
Asset type
Stock
Exchange
KRX
Currency
KRW

What changed lately

Latest news

GC Biopharma's Hunter Syndrome Treatment 'Hunterase' Receives Drug Approval in India and Taiwan

Aug 24, 2026

Closed ₩130,300 (+6.7%) on Aug 24, 2026

GC Biopharma Announces Lunch Symposium and Poster Presentations on IVIG Product Characterization at the 2026 CIS Annual Meeting

May 4, 2026

Closed ₩135,800 (-1.2%) on May 6, 2026

GC Biopharma Announces Presentation on Aggregation Profiles of Commercial IVIG Products at NHIA 2026

Apr 16, 2026

Closed ₩151,200 (+1.1%) on Apr 17, 2026

GC Biopharma Enhances IVIG Safety Profile with Advanced Prothrombotic Impurity Detection Technology

Apr 6, 2026

Closed ₩140,000 (-0.4%) on Apr 6, 2026

GC Biopharma Receives Marketing Authorization for Varicella Vaccine 'BARYCELA Inj.' in Guatemala

Mar 26, 2026

Closed ₩148,300 (-0.5%) on Mar 26, 2026

GC Biopharma Publishes a Comprehensive Review Paper Summarizing 30 Years of Accumulated Data on Its Proprietary Varicella Vaccine Strain, 'MAV/06'

Mar 11, 2026

Closed ₩151,400 (-0.1%) on Mar 11, 2026

GC Biopharma Secures IND Approval for Phase 1 Clinical Trial of COVID-19 mRNA Vaccine in Korea

Dec 22, 2025

Closed ₩159,700 (-2.7%) on Dec 23, 2025

GC Biopharma Ships First Doses of World's First Recombinant Anthrax Vaccine, 'BARYTHRAX inj.'

Dec 8, 2025

Closed ₩133,100 (-1.7%) on Dec 8, 2025

GC Biopharma's Varicella Vaccine Strain 'MAV/06' Listed in WHO Position Paper

Dec 2, 2025

Closed ₩137,500 (+0.2%) on Dec 2, 2025

GC Biopharma Supports New Insights into Education, Safety, and Patient Outcomes in Ig Therapy Care at the 2025 IgNS Annual Meeting

Nov 6, 2025

Closed ₩128,400 (-3.2%) on Nov 7, 2025

All GC Biopharma Corp. news

Decks

GC Biopharma Corp. on 6ix

News releases
11 in the last 12 months · 23 in all · newest Aug 24, 2026 · oldest 2025
Decks
3 decks · latest Jan 31, 2024

Log in to ask 6ix AI your own questions about GC Biopharma Corp.